Vitrolife AB (publ)

OM:VITR Stock Report

Market Cap: SEK 29.2b

Vitrolife Management

Management criteria checks 2/4

Vitrolife's CEO is Bronwyn Brophy O´Connor, appointed in Aug 2023, has a tenure of 1.33 years. total yearly compensation is SEK7.44M, comprised of 74.5% salary and 25.5% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth SEK4.17M. The average tenure of the management team and the board of directors is 1.2 years and 6.9 years respectively.

Key information

Bronwyn Brophy O´Connor

Chief executive officer

SEK 7.4m

Total compensation

CEO salary percentage74.5%
CEO tenure1.3yrs
CEO ownership0.01%
Management average tenure1.2yrs
Board average tenure6.9yrs

Recent management updates

Recent updates

Is Vitrolife (STO:VITR) A Risky Investment?

Nov 27
Is Vitrolife (STO:VITR) A Risky Investment?

Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Aug 21
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next

Jul 20
Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next

Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth

Jul 18
Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth

Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt

Apr 03
Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Mar 07
A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Feb 05
Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion

Jan 05
Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion

Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching

Dec 15
Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching

Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Nov 27
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Is Vitrolife (STO:VITR) A Risky Investment?

Nov 06
Is Vitrolife (STO:VITR) A Risky Investment?

An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued

Aug 25
An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued

Vitrolife (STO:VITR) Could Easily Take On More Debt

Aug 03
Vitrolife (STO:VITR) Could Easily Take On More Debt

Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?

May 26
Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?

Is Vitrolife (STO:VITR) A Risky Investment?

Jan 23
Is Vitrolife (STO:VITR) A Risky Investment?

Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly

Oct 18
Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly

Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Sep 09
Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Is Vitrolife (STO:VITR) A Risky Investment?

Jul 07
Is Vitrolife (STO:VITR) A Risky Investment?

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

May 26
A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Vitrolife (STO:VITR) Seems To Use Debt Rather Sparingly

Mar 31
Vitrolife (STO:VITR) Seems To Use Debt Rather Sparingly

Estimating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Feb 07
Estimating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

CEO Compensation Analysis

How has Bronwyn Brophy O´Connor's remuneration changed compared to Vitrolife's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 4b

Jun 30 2024n/an/a

-SEK 4b

Mar 31 2024n/an/a

-SEK 4b

Dec 31 2023SEK 7mSEK 6m

-SEK 4b

Compensation vs Market: Bronwyn's total compensation ($USD671.27K) is below average for companies of similar size in the Swedish market ($USD982.45K).

Compensation vs Earnings: Insufficient data to compare Bronwyn's compensation with company performance.

CEO

Bronwyn Brophy O´Connor (50 yo)

1.3yrs

Tenure

SEK 7,439,000

Compensation

Ms. Bronwyn Brophy O´Connor is President and Chief Executive Officer at Vitrolife AB (publ) since joining from August 01, 2023. She has an impressive track record as a leader of global Life science and Med...

Leadership Team

NamePositionTenureCompensationOwnership
Bronwyn Brophy O´Connor
CEO & President1.3yrsSEK 7.44m0.014%
SEK 4.2m
Helena Wennerström
Acting Chief Financial Officerno datano datano data
Claus Bisgaard
Senior Vice President of Technologiesno datano data0.00028%
SEK 81.7k
Guillermo Ferrando
Vice President Strategy & Corporate development1.9yrsno datano data
Olivia Natens
Senior Vice President of Sales & Marketingless than a yearno datano data
Frank Pettersson
Acting Senior Vice President of HR & Sustainability1.2yrsno data0.0013%
SEK 382.4k
Rickard Ericsson
Senior Vice President of Consumablesless than a yearno data0.0061%
SEK 1.8m
Ricardo Capella
Senior Vice President Genetic Services2.9yrsno data0.0044%
SEK 1.3m

1.2yrs

Average Tenure

53.5yo

Average Age

Experienced Management: VITR's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Henrik Blomquist
Director5.6yrsSEK 883.00k0.0081%
SEK 2.4m
Jon Sigurdsson
Chairman of the Board9.9yrsSEK 16.30m0.022%
SEK 6.6m
Lars Holmqvist
Independent Director6.9yrsSEK 450.00kno data
Pia Marions
Independent Director11.7yrsSEK 500.00k0.0037%
SEK 1.1m
Karen Soerensen
Independent Director4.5yrsSEK 500.00kno data

6.9yrs

Average Tenure

62yo

Average Age

Experienced Board: VITR's board of directors are considered experienced (6.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 10:15
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vitrolife AB (publ) is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik CasselABG Sundal Collier Sponsored
null nullABG Sundal Collier Sponsored
Kallum TitchmarshBofA Global Research